Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Last Updated: February 9, 2023

Details for Patent: 8,920,392

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 8,920,392 protect, and when does it expire?

Patent 8,920,392 protects GELNIQUE and is included in one NDA.

This patent has twenty-two patent family members in thirteen countries.

Summary for Patent: 8,920,392

Title:	Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
Abstract:	The invention relates to a method for treating overactive bladders and a device for storing and administering non-occluded oxybutynin topical compositions.
Inventor(s):	Gochnour; Scott (Salt Lake City, UT), Subramanyan; Venkatesh (Salt Lake City, UT), Kimball; Michael W. (Salt Lake City, UT)
Assignee:	Watson Laboratories, Inc. (Salt Lake City, UT)
Application Number:	12/435,895
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,920,392
Patent Claim Types: see list of patent claims	Composition; Compound; Device; Formulation; Use;

Drugs Protected by US Patent 8,920,392

Subscribe to access the full database, or Try it Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Allergan	GELNIQUE	oxybutynin chloride	GEL;TRANSDERMAL	022204-001	Jan 27, 2009		RX	Yes	Yes	See Plans and Pricing	See Plans and Pricing				TREATMENT OF OVERACTIVE BLADDER BY APPLICATION OF OXYBUTYNIN CHLORIDE GEL TO SKIN	See Plans and Pricing
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 8,920,392

Subscribe to access the full database, or Try it Free
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2010246103	See Plans and Pricing
Brazil	PI1015542	See Plans and Pricing
Canada	2760867	See Plans and Pricing
Canada	2821174	See Plans and Pricing
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts

Baxter

Dow

Johnson and Johnson

McKinsey

Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.